VCEL Company Profile and Key Details

Q: Who are the executives of VCEL?

Mr. Michael HalpinChief Operating OfficerDr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.Chief Medical OfficerMr. Jonathan SiegalPrincipal Accounting Officer, Vice President & Corporation ControllerMr. Roland DeAngelisSenior Vice President of Commercial OperationsMs. Heidi HassenSenior Vice President of HRMr. Eric BurnsVice President of Fin. & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporation Devel. & StrategyMr. Dominick C. Colangelo Esq.Chief Executive Officer, Pres & DirectorMr. Joseph Anthony Mara Jr.Chief Financial Officer & Treasurer

NASDAQ : VCEL

Vericel

$32.50

0.21+0.65%

At Close 4:00 PM

65.8

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Vericel Corporation (VCEL) stock surged +0.65%, trading at $32.50 on NASDAQ, up from the previous close of $32.29. The stock opened at $33.00, fluctuating between $32.11 and $33.03 in the recent session.

Stock Snapshot

32.29

Prev. Close

1.65B

Market Cap

32.1111

Day Low

101.56

P/E Ratio

0.32

EPS (TTM)

0.16

Cash Flow per Share

Open

50.76M

Number of Shares

33.03

Day High

98.9%

Free Float in %

4.73

Book Value

423K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 17, 2026	32.61	33.03	32.11	32.50	432.17K
Mar 16, 2026	32.79	33.47	32.20	32.29	621.16K
Mar 13, 2026	32.50	32.65	31.16	32.53	604.21K
Mar 12, 2026	32.27	33.01	31.70	32.11	929.16K
Mar 11, 2026	33.25	33.29	32.73	32.88	340.08K
Mar 10, 2026	33.89	34.79	32.53	33.40	507.15K
Mar 09, 2026	33.19	34.36	32.85	34.12	550.94K
Mar 06, 2026	33.50	33.79	33.00	33.71	413.19K
Mar 03, 2026	34.32	34.86	33.60	34.39	424.95K
Mar 02, 2026	34.55	36.10	34.28	35.36	531.53K
Feb 27, 2026	36.66	36.75	35.01	35.68	522.91K
Feb 26, 2026	37.31	38.49	35.69	37.68	608.51K
Feb 25, 2026	38.14	38.38	36.63	37.09	658.67K
Feb 24, 2026	38.24	38.67	37.76	38.25	450.63K
Feb 23, 2026	38.03	38.65	37.39	38.25	510.47K
Feb 20, 2026	37.88	38.98	37.01	38.09	513.65K
Feb 19, 2026	37.23	38.38	36.77	38.17	475.14K
Feb 18, 2026	36.56	37.87	35.96	37.41	327.29K
Feb 17, 2026	36.06	37.32	35.47	36.82	463.27K
Feb 13, 2026	34.22	36.17	34.13	35.96	446.04K

Contact Details

Cambridge, MA 02139

United States

https://vcel.com 617 588 5555

About Company

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Stock Peers

REGN

2.14+0.28%

Regeneron Pharmaceuticals, Inc.$759.05 ARGX

2.73+0.39%

argenx SE$706.03 UTHR

5.72001+1.07%

United Therapeutics Corporation$540.02 VRTX

-3.61-0.77%

Vertex Pharmaceuticals Incorporated$462.49 MDGL

2.35+0.53%

Madrigal Pharmaceuticals, Inc.$443.18 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.51+0.47%

Alnylam Pharmaceuticals, Inc.$320.42 PRAX

-1.62-0.53%

Praxis Precision Medicines, Inc.$303.38 KRYS

6.17+2.47%

Krystal Biotech, Inc.$256.33 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Vericel Corporation (NASDAQ:VCEL) closed at $32.50 USD, gaining $0.21 (0.65%) from the previous close of $32.29. The stock is currently mid-range between its 52-week high and low $29.24 and $48.75. With a market capitalization of about $1.65 billion, Vericel Corporation is classified as a small-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 514.09 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Vericel Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dominick C. Colangelo, the company employs approximately 357 people and listed since February 04, 1997. Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 2.91%, SMA50 1.66%, SMA200 0.47%). The stock’s 14-day RSI is 53.51 (neutral), while the ATR of 1.72 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.0% below its high and over 28.86% above its low. Average 10-day trading volume of 569.27 thousand shares is slightly above the 3-month average of 505.99 thousand, indicating heightened recent market interest.

Valuation Metrics

Vericel Corporation trades at a P/E ratio of 100.42, slightly above the S&P 500 average, with a price-to-sales ratio of 6.02 and a price-to-book ratio of 4.68 trading at moderately above to book value. The P/FCF stands at 47.46, also below market averages.

Dividend & Fair Value

Vericel Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 65.35% annually over the next five years. The latest quarter delivered EPS of $0.10. The next quarter is forecast at $0.41. Next year's EPS is expected at $144.02. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $41.00. The high target offers 106.15% upside. The low target suggests 26.15% downside. The mean target is $55.00. This offers 69.23% upside. Vericel Corporation earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -588.75%. The prior quarter beat by -75.0%. Over the last six quarters, Apple has recorded several small beats. These include -3.83% in August 01, 2024.

Shareholding & Insider Activity

Vericel Corporation has 50.46 million shares outstanding. The public float is 49.90 million shares, elevated short interest at 14.14% of float. This equals 5.50 million shares. The short ratio is 9.04 days. Institutional investors hold 108.11% of the float. Insiders own 1.05%. Colangelo Dominick holds 260.35 thousand shares, MICHEL GERARD J has 123.18 thousand shares and Hopper Jonathan Mark has 66.56 thousand shares. Over the past six months, insider transactions show net selling. They sold 65.96 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Vericel generated $197.52M in revenue, or $4.15 per share. Gross margin was 68.64%, operating margin -3.27%, and net profit margin -1.61%. Returns are negative, with ROA at -0.90% and ROE at -1.41%.
On valuation metrics, Vericel trades at a P/E of 100.42, P/S of 6.02 and P/B of 4.68. The current ratio is 5.03 and quick ratio is 4.68. Operationally, the company’s inventory turnover is 4.02 and cash conversion cycle is 120.77 days. Debt-to-equity is 0.28, supported by a cash flow-to-debt ratio of 0.53.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Vericel posted revenue of $197.52M, down slightly from $164.37M in the prior quarter. Gross profit was $135.58M (margin 68.64%). Operating income was - $6.46M (margin -3.3%). Net income was- $3.18M (EPS - $0.07).
The company ended the quarter with $127.34M in cash and short-term investments, a total debt of $88.14M, and net debt of $1.28M. Total assets were $353.66M, with equity of $225.95M. Financials further reflected stability, with operating cash flow of $35.31M, free cash flow of $7.80M, and capital expenditures of - $27.51M.

Price Forecast & Outlook

Our AI price prediction model suggests that Vericel Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.66%, with price expected at $28.71 by March 31, 2026, within a range of $27.37 to $30.06 3-Month Outlook: Projected fall of -17.45%, reaching $26.83 by June 15, 2026, with a range of $25.19 to $28.51. 1-Year Outlook: Projected gain of 2.83%, with price at $33.42 by March 17, 2027, within a range of $30.59 to $36.95.

Key Takeaways

Vericel Corporation (NASDAQ:VCEL) shares are flat 0.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vericel Corporation trading at a premium to the broader market with a P/E of 100.42. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.97, suggesting 26.06% upside. Our AI forecast model points to short-term weakness (-11.66% over two weeks), a medium-term fall (-17.45% over three months), and a longer-term gain (2.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Vericel Corporation (VCEL) stock price?

Vericel Corporation (NASDAQ: VCEL) stock price is $32.50 in the last trading session. During the trading session, VCEL stock reached the peak price of $33.03 while $32.11 was the lowest point it dropped to. The percentage change in VCEL stock occurred in the recent session was 0.65% while the dollar amount for the price change in VCEL stock was $0.21.

VCEL's industry and sector of operation?

The NASDAQ listed VCEL is part of Biotechnology industry that operates in the broader Healthcare sector. Vericel Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VCEL?

Mr. Michael Halpin
Chief Operating Officer
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.
Chief Medical Officer
Mr. Jonathan Siegal
Principal Accounting Officer, Vice President & Corporation Controller
Mr. Roland DeAngelis
Senior Vice President of Commercial Operations
Ms. Heidi Hassen
Senior Vice President of HR
Mr. Eric Burns
Vice President of Fin. & Investor Relations
Mr. Patrick J. Fowler
Senior Vice President of Corporation Devel. & Strategy
Mr. Dominick C. Colangelo Esq.
Chief Executive Officer, Pres & Director
Mr. Joseph Anthony Mara Jr.
Chief Financial Officer & Treasurer

How VCEL did perform over past 52-week?

VCEL's closing price is 11.15% higher than its 52-week low of $29.24 where as its distance from 52-week high of $48.75 is -33.33%.

How many employees does VCEL have?

Number of VCEL employees currently stands at 357.

Link for VCEL official website?

Official Website of VCEL is: https://vcel.com

How do I contact VCEL?

VCEL could be contacted at phone 617 588 5555 and can also be accessed through its website. VCEL operates from 64 Sidney Street, Cambridge, MA 02139, United States.

How many shares of VCEL are traded daily?

VCEL stock volume for the day was 423K shares. The average number of VCEL shares traded daily for last 3 months was 514.09K.

What is the market cap of VCEL currently?

The market value of VCEL currently stands at $1.65B with its latest stock price at $32.50 and 50.76M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	357
Beta	1.19
Sales or Revenue	$197.52M
5Y Sales Change%	0.838%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VCEL Company Profile and Key Details

Vericel

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook